
AOD-9604 Peptide for Sale
Published by Peptara Labs · Updated · How we research and check our pages
Growth Hormone Fragment, Studied in Mice
AOD-9604 peptide from Peptara Labs (peptaralabs.io) is a 10mg research-grade vial for $74 USD, the AOD-9604 Black Friday price: 45% off the regular $135, and it ships as soon as stock arrives. Its batch certificate of analysis is pending, so no purity figure is claimed yet. It is sold for research use only.
Black Friday price, 45% off, ends November 30
Black Friday price, 45% off, ends November 30
Flat $35 tracked shipping10mg per vial
Ships as soon as stock arrives
$74 USD
Was $135
Add 2 more, unlock 50%
Vials of any product count together in your cart: 1 to 2 vials 45% off, 3 to 4 vials 50% off, 5 to 9 vials 55% off, 10 or more 60% off. No code is added on top.

Shipping, delivery and certificate status
- Shipping
- Flat $35, tracked worldwide to supported markets
- Delivery
- Ships as soon as stock arrives · After dispatch: 5 to 10 business days
- Included
- Vial · Batch certificate pending · Order support on WhatsApp
Buyer facts
What do you get when you buy AOD-9604 from Peptara Labs?
One sealed 10mg vial of lyophilized AOD-9604 powder. The order contains this vial only.
| Detail | AOD-9604 | Where to check it |
|---|---|---|
| Compound | AOD-9604, also written AOD9604 | Identity checks below |
| Vial | 10mg, sealed lyophilized powder | Vial listing |
| Price | $74 USD, the AOD-9604 Black Friday price: 45% off the regular $135 | Order panel above |
| Availability | Pre-order. Ships as soon as stock arrives. Delivery follows dispatch. | Shipping note above |
| Certificate | Batch certificate pending | Certificate status |
| Use | Laboratory research only | Research-use label |
Your order includes the vial. Batch certificate pending. Delivery details are confirmed with your order. Order support is available on WhatsApp.
Share or cite this page
Sources: PubChem, CID 71300630.
Before you buy
What should you check before you buy AOD-9604?
AOD-9604, AOD9604 and the seller label "fragment 176-191" often refer to this research peptide. The safety summary describes its structure as positions 177 to 191 of human growth hormone with an added tyrosine.
A certificate should identify the compound by mass spectrometry and report purity by HPLC. PubChem lists formula C78H123N23O23S2 and molecular weight 1815.1 g/mol. A name on a listing does not replace those checks. This batch certificate is pending and no measured purity is claimed.
The peptide purity guide explains the checks, and the certificates page shows current status.
Sources: Stier et al., 2013, J Endocrinol Metab, DOI 10.4021/jem157w; PubChem, CID 71300630.
The short answer
What is AOD-9604?
AOD-9604 is a 16 amino acid peptide built from the end of human growth hormone with an added tyrosine. Researchers designed it to keep the part tied to fat breakdown while leaving out other growth hormone signals.
That design is a research idea. Mouse and rat studies measured fat metabolism, and six human trials were later summarized for safety. This vial is research material and is not an approved weight-loss medicine.
Sources: Stier et al., 2013, J Endocrinol Metab, DOI 10.4021/jem157w; Ng et al., 2000, Horm Res, PMID 11146367; Heffernan et al., 2001, Endocrinology, PMID 11713213; FDA safety-risk listing, content current April 22, 2026.
The science
How was AOD-9604 designed to work?
The idea separates lipolysis, the breakdown of stored fat, from lipogenesis, the building of new fat. In obese mice, researchers measured lower body weight and fat over 14 days and a return of beta-3 receptor RNA toward lean-animal levels. Mice without that receptor did not show the same weight change, although a short-term test still found higher energy use.
A rat study measured weight gain over 19 days. In obese Zucker rats, it was less than half that of controls, with no adverse change in insulin sensitivity. The six-trial human safety summary found no change in IGF-1. These findings describe the study models and do not predict a personal result.
Fat-metabolism hypothesis
A small growth hormone fragment was designed around fat-breakdown signaling.
Beta-3 receptor link
Mouse comparisons tested whether the beta-3 receptor was needed for the weight change.
IGF-1 remained unchanged
The human safety summary recorded no change in IGF-1 across six trials.
Sources: Heffernan et al., 2001, Endocrinology, PMID 11713213; Ng et al., 2000, Horm Res, PMID 11146367; Stier et al., 2013, J Endocrinol Metab, DOI 10.4021/jem157w.
Applications
What has AOD-9604 been studied in?
Obesity models
Mouse and rat studies measured body fat, weight change and metabolic signals.
Insulin sensitivity
A rat study used clamp testing to examine glucose handling.
Human safety trials
A paper summarized six controlled trials with 893 participants.
Knee cartilage damage
A rabbit model examined cartilage tissue scores.
Sources: Heffernan et al., 2001, Endocrinology, PMID 11713213; Ng et al., 2000, Horm Res, PMID 11146367; Stier et al., 2013, J Endocrinol Metab, DOI 10.4021/jem157w; Kwon and Park, 2015, Ann Clin Lab Sci, PMID 26275694.
Comparison
AOD-9604 vs tesamorelin and other growth hormone peptides
AOD-9604 is a hormone fragment. The other molecules below raise or imitate signals that lead to growth hormone release. Their study records answer different questions.
| Compound | What it is | Effect on IGF-1 | Study record |
|---|---|---|---|
| AOD-9604 | 16 amino acid growth hormone fragment | No change in six trials | A six-trial human safety summary, plus animal metabolism studies |
| Tesamorelin | GHRH analog | Rose 81% in the cited trial | 412 people with HIV: visceral fat fell 15.2% versus a 5.0% rise with placebo |
| CJC-1295 | Long-acting GHRH analog | Sustained increase in healthy adults | Controlled human study of growth hormone and IGF-1 signals |
| Ipamorelin | Selective growth hormone secretagogue | Not established by the cited paper | The early paper identified its selective growth hormone signal |
| MK-677 | Ghrelin mimetic | Not quantified on this page | A randomized trial found higher fasting glucose and lower insulin sensitivity |
Separate pages cover tesamorelin, CJC-1295 and ipamorelin, and MK-677. The AOD-9604 comparison guide covers a separate medicine class.
Sources: Stier et al., 2013, J Endocrinol Metab, DOI 10.4021/jem157w; Falutz et al., 2007, N Engl J Med, PMID 18057338; Teichman et al., 2006, J Clin Endocrinol Metab, PMID 16352683; Raun et al., 1998, Eur J Endocrinol, PMID 9849822; Nass et al., 2008, Ann Intern Med, PMID 18981485.
Evidence
What did the AOD-9604 studies report?
Mouse metabolism study
Model: Obese mice and mice without the beta-3 receptor.
Reported: Researchers measured weight, fat, receptor RNA and energy use.
Rat insulin-sensitivity study
Model: Obese Zucker rats.
Reported: Weight gain was lower than controls, with no adverse change in insulin sensitivity.
Six-trial safety review
Model: 893 human participants across six controlled trials.
Reported: The paper recorded safety findings and no change in IGF-1.
Rabbit cartilage study
Model: A rabbit model of knee cartilage damage.
Reported: Researchers assessed cartilage tissue scores.
The human trial ledger: six trials, 893 people
| Trial code | Phase | People | Length | What it measured |
|---|---|---|---|---|
| METAOD001 | I | 15 healthy men | Single sessions | Safety |
| METAOD002 | IIa | 23 obese men | Single sessions | Safety |
| METAOD003 | IIa | 17 obese men | Single sessions | Safety |
| METAOD004 | IIa | 36 obese men | 7 days | Safety |
| METAOD005 | IIb | 300 obese adults | 12 weeks planned, 14-week period | Efficacy and safety |
| METAOD006 | IIb | 502 obese adults randomized | 24 weeks | Efficacy and safety |
The safety summary found no change in IGF-1, no adverse effect on glucose tolerance and no antibodies. It reported no withdrawals or serious adverse events tied to AOD-9604, with safety similar to placebo. The paper reports safety and does not supply the weight-change findings needed to judge efficacy.
The FDA lists AOD-9604 among substances nominated for compounding and then withdrawn. Its page notes immune-reaction risk, limited safety information and serious adverse events that may be linked to the compound, with the cause unclear. That regulatory warning sits alongside the earlier trial report; neither establishes that this research vial is safe for a person.
Sources: Heffernan et al., 2001, Endocrinology, PMID 11713213; Ng et al., 2000, Horm Res, PMID 11146367; Stier et al., 2013, J Endocrinol Metab, DOI 10.4021/jem157w; Kwon and Park, 2015, Ann Clin Lab Sci, PMID 26275694; FDA safety-risk listing, content current April 22, 2026.
What is not known
What is still unknown about AOD-9604?
The references on this page do not establish a peer-reviewed half-life figure or long-term human safety. A number borrowed from another growth hormone fragment would not answer that gap.
ClinicalTrials.gov searches for AOD9604 and AOD-9604 returned zero registered studies on October 7, 2026. The safety paper describes six trials notified in Australia, so that registry search does not erase the trial record.
Sources: Stier et al., 2013, J Endocrinol Metab, DOI 10.4021/jem157w; ClinicalTrials.gov searches, October 7, 2026; FDA safety-risk listing, content current April 22, 2026.
Research timeline
How the AOD-9604 record was built
Research timeline
How the AOD-9604 record was built
Research timeline
How the AOD-9604 record was built
2000: rat metabolism
Researchers measured weight gain and insulin sensitivity in obese Zucker rats.
2001: beta-3 receptor studies
Mouse studies compared animals with and without the beta-3 receptor to test its role in fat metabolism.
2013: six-trial safety summary
A paper summarized safety findings from six controlled trials involving 893 people.
2015: knee cartilage research
Researchers assessed tissue scores in a rabbit model of knee cartilage damage.
2026: FDA safety-risk listing
The FDA listed AOD-9604 among compounding nominations that were withdrawn and described safety concerns.
Your Kit
What's Included

$74 USD Was $135 USD
Flat $35 tracked shipping · Ships as soon as stock arrives · Batch certificate pending · Order support on WhatsApp
Black Friday price, 45% off, ends November 30
AOD-9604 10mg Vial
10mg per vial
Batch certificate
Batch certificate pending
Delivery
Ships as soon as stock arrives · After dispatch: 5 to 10 business days
Order support
Contact our team about your order or batch certificate.
Your order includes the vial. Batch certificate pending. Delivery details are confirmed with your order. Order support is available on WhatsApp.
Your Research Order
AOD-9604 research vial, batch certificate status, delivery and order support.
Batch certificate
Batch certificate pending
Delivery
Ships as soon as stock arrives · After dispatch: 5 to 10 business days
Order support
Contact our team about your order or batch certificate.
Research and citations
Peer-reviewed and regulator sources
- Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7 to 15. DOI 10.4021/jem157w.
- Heffernan et al. Endocrinology. 2001;142(12):5182 to 5189. PMID 11713213. DOI 10.1210/endo.142.12.8522.
- Ng et al. Horm Res. 2000;53(6):274 to 278. PMID 11146367. DOI 10.1159/000053183.
- Kwon and Park. Ann Clin Lab Sci. 2015;45(4):426 to 432. PMID 26275694.
- Falutz et al. N Engl J Med. 2007;357(23):2359 to 2370. PMID 18057338. DOI 10.1056/NEJMoa072375.
- Teichman et al. J Clin Endocrinol Metab. 2006;91(3):799 to 805. PMID 16352683.
- Raun et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552 to 561. PMID 9849822.
- Nass et al. Ann Intern Med. 2008;149(9):601 to 611. PMID 18981485.
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current April 22, 2026.
- National Center for Biotechnology Information. PubChem compound summary, AOD-9604, CID 71300630.
- ClinicalTrials.gov searches for AOD9604 and AOD-9604 on October 7, 2026: zero registered studies.
Explore more
Related guides, comparisons, and compounds studied for related endpoints
Tesamorelin
A different molecule with controlled trial evidence.
CJC-1295 and ipamorelin
Growth hormone signaling research.
MK-677
Ghrelin-mimetic research and its limits.
MOTS-c
A separate metabolic research record.
5-Amino-1MQ
A small molecule studied in metabolic models.
AOD-9604 comparison guide
How a growth hormone fragment differs from a separate medicine class.
Fat-metabolism peptide research
Research models, evidence and limits.
Growth hormone peptides explained
The difference between hormone fragments and signal molecules.
Peptide glossary
Definitions of the research terms on this page.
How to verify peptide purity
Identity and purity checks for a batch certificate.
Certificates of analysis
Published certificates and pending status.
Where to buy research peptides
Questions to ask a research supplier.
Questions
Buying AOD-9604: FAQ
How much is AOD-9604 at Peptara Labs?
A 10mg research vial is $74 USD, the AOD-9604 Black Friday price: 45% off the regular $135. Ships as soon as stock arrives. Delivery follows dispatch. It is sold for research use only.
Where can I buy AOD-9604?
Peptara Labs lists AOD-9604 as a 10mg research vial on this page. Its batch certificate is pending, so no purity figure is claimed yet.
Is a batch certificate available for this AOD-9604 vial?
The batch certificate of analysis is pending. No purity figure, test date or batch number is claimed before a certificate is released.
AOD-9604 research FAQ
What is AOD-9604?
AOD-9604 is a 16 amino acid peptide built from the end of human growth hormone, positions 177 to 191, with an added tyrosine. It was made to keep the part tied to fat breakdown and leave out other hormone signals.
Is AOD-9604 the same as growth hormone?
No. AOD-9604 is a small fragment with an added tyrosine, rather than the whole hormone. The six trials summarized in 2013 found no change in IGF-1.
Does AOD-9604 raise IGF-1?
Six human trials summarized in 2013 found no change in IGF-1 levels. GHRH analogs such as tesamorelin have a different structure and raised IGF-1 in research.
What side effects did AOD-9604 trials record?
The 2013 summary of six controlled trials reported a safety profile similar to placebo, with no antibodies found. The FDA notes serious adverse events that may be linked to AOD-9604, though the cause is not clear.
Is AOD-9604 the same as tesamorelin?
No. Tesamorelin is a GHRH analog that raises growth hormone and IGF-1, and it has a large controlled trial in people with HIV. AOD-9604 is a fragment of growth hormone that did not raise IGF-1 in trials.
Is AOD-9604 better than tesamorelin in fat-metabolism research?
The cited studies do not compare them directly. Tesamorelin has controlled evidence in people with HIV. The AOD-9604 human paper cited here reports safety, rather than weight-change findings, so it cannot establish a ranking.
Is AOD-9604 an approved weight-loss medicine?
No. AOD-9604 is handled here as a research material. Its listing on the FDA compounding safety-risk page does not make it an approved medicine.
Sources: Stier et al., 2013, J Endocrinol Metab, DOI 10.4021/jem157w; Falutz et al., 2007, N Engl J Med, PMID 18057338; FDA safety-risk listing, content current April 22, 2026.
Order AOD-9604, 10mg research vial
Order AOD-9604. Ships as soon as stock arrives · After dispatch: 5 to 10 business days. Order support on WhatsApp.
Order NowBatch certificate pending · Ships as soon as stock arrives · Order support on WhatsApp